Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics' stock fell 19.23% due to concerns that their collaborative project with Johnson & Johnson, JNJ-2113, may be scaled back. JNJ-2113 did not meet the desired level of "biologic-like" efficacy required by Johnson & Johnson, leading to doubts about its potential for further development.

https://www.evaluate.com/vantage/articles/news/trial-results-snippets/protagonist-investors-flake-psoriasis-pill-disappoints